The IASLC Fellowship/Young Investigator Award applications are due January 10, 2011. We would like to encourage as many as possible to apply for these fellowships/young investigator awards, particularly from Asia which has been underrepresented.
The World Lung Conference in Amsterdam July 3-7, 2011 is approaching and we would encourage members to start preparing this abstracts as early as possible. We expect this conference to be a historical success taking recent scientific developments in lung cancer screening and therapy into account.
The IASLC has just had two very successful regional meetings; 4th Asia Pacific Lung Cancer Conference in Seoul, Korea (about 1000 participants) and the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology (more than 700
participants). IASLC is in the planning process for the ESMO IASLC meeting 2012 in Geneva and the Latin America meeting in Brazil 2012.
The IASLC has received 4 bids to host the World Conference on Lung Cancer 2017 in Europe. The review process has started and it is expected that a final decision will be made at the meeting in Amsterdam, July 2011.
New IASLC educational activities are planned and the IASLC Webinar series starts January 2011 (see below).
We would also like to pay attention to the iPAD application of the new IASLC staging System (see below).
Finally, the IASLC Executive Committee and the Staff wish all the members Happy Holidays and a healthy and successful year 2011!
Fred R. Hirsch, MD, PhD
IASLC Lung Cancer Fellowship Award - 2 years duration
IASLC Young Investigators Award - 2 years duration
IASLC/PCF Prevent Cancer Foundation Fellowship Award - 2 years duration
The IASLC is proud to announce the annual IASLC Fellowship and Young Investigators Programs.
Overall, there are 3 or more awards for two years each and at least one applicant from each region (North America, Europe and Rest of the World) will be funded. There are awards in prevention and translational lung cancer research that are jointly sponsored with the Prevent Cancer Foundation, (PCF), through educational grants from Eli Lilly. There are unrestricted awards in any field of lung cancer research supported by educational grants from Amgen, Genentech, OSI, Eli Lilly, the IASLC and other sponsors.
This year at least 3 new unrestricted awards of $40,000 each year for 2 years are available for competition.
We are now requesting application for these Fellowships and Young Investigator awards to be awarded in 2011 - 2012. The goal is to reward scientific excellence and to encourage innovative investigations in the field of lung cancer prevention research and translational research with a potential impact on the management of lung cancer. The applications will be evaluated by a Scientific Review Panel; the deadline for submission of the application is January 10, 2011. A decision on applications will be reached by March 2010.
Application forms can be found at the website: www.iaslc.org
Please e-mail you application to: pia.Hirsch@ucdenver.edu latest January 10, 2011.
14th World Conference on Lung Cancer
The Scientific Committee of the 14th World Conference on Lung Cancer is inviting the submission of Scientific Abstracts and pleased to advise that online abstract submission is now open. Submission Categories Authors are asked to submit abstracts under one of the official categories, found on the Conference website athttp://www.2011worldlungcancer.org/call_for_papers.html. Submission Guidelines Research work should be original and innovative. Work can be presented prior to the 14th WCLC, but MUST include new information
- Abstracts must be submitted electronically
- Abstracts will be accepted in English only
- Abstracts should not exceed 500 words in length
- Tables may be included and each will count as 100 words
- A maximum of 2 images may be included, each will count as 100 words
- There is no fee for submitting an abstract
- There is no limit to the number of abstracts you may submit (however an individual may not be offered more than 2 oral presentations)
- An international panel of reviewers will review all abstracts anonymously
- All Abstracts accepted by the Scientific Committee will be published in the Journal of Thoracic Oncology (JTO) and on the Conference website prior to the Conference and it is mandatory to agree to this at the time of submission
- Financial Disclosure information needs to be completed for EACH co-author at the time of submission through the online abstract submission form, however, information can be provided by the submitting author
Abstract Submission Deadline: Friday, 25 February 2011 (23:59 PST)
New for 2011—IASLC Web-based Education Programs
Starting January 2011, IASLC is introducing new educational programs for its members and for healthcare professionals who are managing patients with lung cancer. The first program titled, “New Developments in Non-Small Cell Lung Cancer” features Professor Peter Goldstraw, MD, in a two-part presentation, that reviews the fundamentals of the new lung cancer staging system and examines the role of the TNM staging system of patients with small-cell lung cancer. The new, updated IASLC nodal staging map is also reviewed. In another presentation, Paul Bunn, Jr, MD, address the incorporation of molecular testing into the standard diagnostic workup of patients with NSCLC, and the selection of appropriate treatment for patients. The program concludes with case-study presentations by Drs. Bunn and Harvey I. Pass, illustrating the use of the new staging system and molecular testing.
ASLC Staging Manual:
The IASLC Staging Manual and Handbook in Thoracic Oncologic has now surpassed 35,000 copies sold worldwide. In addition, the Staging Posters and Reference Cards continue to be popular reference aids of the 7th edition staging system for practitioners and tumor boards. IASLC members can continue to order these publications and products at special member pricing (www.iaslcpubs.org; contact email@example.com for further information).
In addition, translations of these publications have been completed or are in process in multiple languages: Chinese, Italian, Japanese, Polish, and Turkish. Discussions about future translations in Spanish, Arabic, and Russian are ongoing.
The new IASLC Staging Manual has been published in different formats. Several years of work from the IASLC Staging Committee and particularly the chair Dr. Peter Goldstraw, has resulted in a formal staging manual. The book and the “pocket-cards” can be ordered at www.iaslc.org
JTO Mobile options
JTO is available for your iPhone, Blackberry, or Android phone, in a view designed for easy reading on a small screen. Type jto.org into your phone’s browser to access the site. You can view current issue table of contents, most viewed articles, most emailed articles, or search across issues. If you have created a user name and password on the desktop version of JTO.org, you can use that same log in information to view full text articles, complete with illustrations.
IASLC Textbook – Editor in Chief:
Harvey I. Pass, MD
Lung Cancer Book from Lippincott: The Fourth Edition of Principles and Practice of Lung Cancer, edited by Harvey I. Pass, MD et al is now available. For more information about the 1040 page book, with 330 illustrations (ISBN-10:0-7817-7365-2) or www.lww.com/product/?978-0-7817-7365-2.
Yale Cancer Center has appointed Roy S. Herbst, M.D., Ph.D., who has had a distinguished career in the development of cancer therapies, to the positions of chief of medical oncology and associate director for translational research. Beginning in March, Herbst will lead the section of medical oncology at Smilow Cancer Hospital at Yale-New Haven — integrating clinical, laboratory and research programs at Yale Cancer Center to bring new treatments to cancer patients. Herbst comes to Yale from the University of Texas MD Anderson Cancer Center. This appointment marks Herbst’s return to New Haven, where he received his undergraduate and masters degrees from Yale.
Renee McGaw has joined the IASLC as Director of PR. She previously spent more than 20 years as a writer and editor for news organizations including the International Herald Tribune in Paris, Knight Ridder Financial News in Geneva, and the Denver Post. She has a master’s degree in journalism from Northwestern University and an undergraduate degree in French from Colorado State University
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.